Reduced Relapse Risk in Acute Myelogenous Leukemia (AML) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients Who Experienced CMV Reactivation: Influence of Donor KIR Genotypes

Anthony S. Stein(University of Hohenheim), Ryotaro Nakamura(City Of Hope National Medical Center), Sandra H. Thomas(City Of Hope National Medical Center), David Senitzer(City of Hope), Ketevan Gendzekhadze(City Of Hope National Medical Center), John A. Zaia(City Of Hope National Medical Center), Joycelynne Palmer(City of Hope), Ni‐Chun Tsai(City of Hope), Stephen J. Forman(City Of Hope National Medical Center)
Blood
December 6, 2014
10.1182/blood.v124.21.669.669
Cited by 1

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k